Neuropathology of Alzheimer’s Disease

By C. Schultz, K. Del Tredici, H. Braak. 2004

650 citations recorded by the source corpus.

Alzheimer’s disease (AD) is a progressive neurodegenerative and dementing disorder that can be detected clinically only in its end phase. AD is the most widespread type of dementia and affects about 10% of individuals older than 65 years and about 40% of individuals older than 80 years of age (1,2). The earliest sign of AD is a subtle decline in memory functions in a state of clear consciousness. Mental capabilities gradually worsen and personality changes appear, followed by deterioration of language functions, impairment of visuospatial tasks, and, in the disease’s final stages, dysfunction of the motor system in the form of a hypokinetic-hypertonic syndrome.

Subfields: Neurology, Physiology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/1dd86de5cf36e10d13eff76c2b3fd662f3983a3a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Neurology

In Physiology

In Psychiatry and Mental health

Citations in the corpus

Cholinesterase inhibitors as Alzheimer's therapeutics (2019, background): “…inhibitors of ache and a β cleaving enzyme 1 (12). in addition, tauopathy is an important aspect of ad pathology, and τ protein hyperphosphorylation leads to the formation of intracellular neurofibrillary tangles of the microtubule‑associated protein τ and subsequent neurode-generation (13,14).”
Microglial Dysfunction and Defective β-Amyloid Clearance Pathways in Aging Alzheimer's Disease Mice (2008, background): “The senile plaque is a pathological hallmark of Alzheimer’s disease (AD) and is composed of -amyloid (A ), activated microglia, astrocytes, and degenerating neurons (Dickson et al., 1988; Selkoe, 2000; Mott and Hulette, 2005).”
Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: The emerging role of oligomeric assemblies (2002, positive): “By deﬁnition, Alzheimer’s disease is characterized by the formation of neuritic plaques and neuroﬁbrillary tangles (NFT) (Khachaturian, 1985; Mirra, 1991; Esiri, 2001).”
Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012, background): “Excellent reviews are available about the molecular characteristics of NFTs and A A Ps (27, 28).”
Role of glutamate and NMDA receptors in Alzheimer’s disease (2016, neutral): “The signiﬁcant synaptic loss and neuronal death manifests the symptoms of Alzheimer’s disease. phosphorylated tau, the substantial loss of synaptic proﬁles [3].”